+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders



The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders



Haematologica 93(5): 787-788




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056194201

Download citation: RISBibTeXText

PMID: 18450736

DOI: 10.3324/haematol.12337


Related references

Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders. Journal of International Medical Research 37(1): 37-46, 2009

Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders. American Journal of Hematology 82(6): 458-459, 2007

Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Internal Medicine Journal 38(6): 422-426, 2008

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Irish Journal of Medical Science 176(2): 105-109, 2007

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian Journal of Medical Research 132: 423-427, 2011

A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders. La Clinica Terapeutica 163(2): 109-113, 2012

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology 14(6): 323-330, 2010

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1): 375-379, 2007

Detection and clinical significance of JAK2 V617F mutation in Chinese and Uyghur patients with chronic myeloproliferative in Xinjiang. Zhonghua Xue Ye Xue Za Zhi 33(12): 1020-1023, 2013

Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. American Journal of Surgical Pathology 31(2): 233-239, 2007

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. Journal of Thrombosis and Haemostasis 5(4): 708-714, 2007

The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. International Journal of Laboratory Hematology 30(5): 415-419, 2008

The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. British Journal of Haematology 136(5): 745-751, 2007

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia (Basingstoke) 20(3): 471-476, 2006

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106(6): 2162-2168, 2005